alexa Tissue Biomarker Impact Factor|Omics Group|Journal Of Molecular Biomarkers And Diagnosis

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Tissue Biomarker Impact Factor

Impact Factor is an indicator of the number of citations within the scientific journals of clinical and medical category. Impact factor is measured based on the frequency with which a journal's articles are cited in scientific publications, is a putative marker of journal quality. Publication ccitation, index of researchers, and journal impact factors are used to measure the impact & importance of research. Journal Impact factor are most widely used metric for measuring the quality of clinical Journal. Clinical Journals impact factor can be improved by using various study methods, includes assigning more referees to check the quality of the submitted articles and thus nominating their journals for indexing in databases. In developing biomarkers (BM) to determine the likelihood that initial breast tumor remains contained in situ, as opposed to becoming invasive. In-tissue testing serves as a gold standard for breast cancer diagnostics, yet the power of high throughput technologies can be realized for diagnostic purposes if emerging technologies can be directly applied to samples obtained by the routine clinical procedure. Although a variety of quantitative methods exist for assaying biofluid-based BM, contemporary proteomic technologies remain impractical for application to archived formalin-fixed paraffin--embedded (FFPE) tissues that (being associated with clinical histories) provide a trove of information for BM discovery. Immunohistochemistry (IHC) remains the tool of choice to examine protein expression in tissue; however, it does not lend itself to the truly continuous measurements needed for BMstudy. We developed the analytic tools and algorithms – without use of sophisticated and expensive equipment-that allow measurements of protein expression in FFPE tissue on a continuous biologically relevant scale, while quantification of relative (rather then absolute) intensity of staining takes into account fluctuations of background staining. Using this approach, we have revealed that women with invasive breast cancer were 4 times more likely to have increased levels of insulin-like growth factor type I receptor and its target, Ras-related protein 1 than women with non-invasive tumors. To facilitate development of novel in--tissue BMs, we are taking advantage of digital multispectral imaging technology and developing pattern-recognition-based image analysis for the core-needle biopsies containing early form of breast cancer, i.e. carcinoma in situ. (Marina A. Guvakova, Developing tissue biomarkers in early breast cancer)
 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
 
adwords